MicroRNA Signature in Metastatic Colorectal Cancer Patients Treated With Anti-EGFR Monoclonal Antibodies

Cappuzzo, Federico; Sacconi, Andrea; Landi, Lorenza; Ludovini, Vienna; Biagioni, Francesca; D’Incecco, Armida; Capodanno, Alessandra; Salvini, Jessica; Corgna, E.; Cupini, Samanta; Barbara, C.; Fontanini, Gabriella; Crinò, Lucio; Blandino, Giovanni

doi:10.1016/j.clcc.2013.11.006

Cited by 49 publications

(35 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This difference also further enhances Wnt activity and may form a feedback loop as a downstream target of Wnt 191 . [164][165][166][167] MiR-126 ↓ Decreased sensitivity to capecitabine and oxaliplatin (XELOX) [168][169] MiR-31 ↑ Decreased sensitivity to 5-fluorouracil …”

Section: Colon Cancer-associated Transcript (Ccat2)mentioning

confidence: 99%

“…These factors are important in predicting the response to particular therapies. MicroRNAs act as positive biomarkers indicating sensitivity to therapy or as negative biomarkers signifying resistance to treatment and assisting in choosing the appropriate treatment regimen (Table 1) [164][165][166][167][168][169][170][171][172][173][174][175][176][177][178][179] .…”

Section: Therapeutic Biomarkersmentioning

confidence: 99%

See 1 more Smart Citation

Colorectal cancer carcinogenesis: a review of mechanisms

Tariq¹,

Ghias²

2016

Cancer Biology &Amp; Medicine

228

138

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the second most common cancer in women and the third most common in men globally. CRC arises from one or a combination of chromosomal instability, CpG island methylator phenotype, and microsatellite instability. Genetic instability is usually caused by aneuploidy and loss of heterozygosity. Mutations in the tumor suppressor or cell cycle genes may also lead to cellular transformation. Similarly, epigenetic and/or genetic alterations resulting in impaired cellular pathways, such as DNA repair mechanism, may lead to microsatellite instability and mutator phenotype. Non-coding RNAs, more importantly microRNAs and long non-coding RNAs have also been implicated at various CRC stages. Understanding the specific mechanisms of tumorigenesis and the underlying genetic and epigenetic traits is critical in comprehending the disease phenotype. This paper reviews these mechanisms along with the roles of various non-coding RNAs in CRCs.

show abstract

Section: Colon Cancer-associated Transcript (Ccat2)mentioning

confidence: 99%

Section: Therapeutic Biomarkersmentioning

confidence: 99%

Colorectal cancer carcinogenesis: a review of mechanisms

Tariq¹,

Ghias²

2016

Cancer Biology &Amp; Medicine

228

138

View full text Add to dashboard Cite

show abstract

“…Regardless, whereas such assays may prove useful for predicting chemotherapeutic response in patients with stage II miRNA profiles have also been evaluated for their ability to predict response to anti-EGFR therapy. A panel consisting of miR-99a, Let-7c, and miR-125b was found to predict enhanced progression-free survival and overall survival after treatment with anti-EGFR mAbs in patients with WT KRAS [64]. Low miR-181a was shown to correlate with poor survival in patients with KRAS-WT CRC after treatment with EGFR-targeting mAbs [65], whereas differential miR-31-3p levels were also shown to predict response [66].…”

Section: Micrornasmentioning

confidence: 95%

Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer

Karapetis

Maru

Waring

et al. 2015

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

The role of biomarker assessment in determining the best therapeutic options for patients with metastatic colorectal cancer has become increasingly complex and important. Biomarkers that predict the efficacy and/or toxicity of such treatments can affect medical decision making, leading to decreased harm and/or costs associated with treatment and improvements in therapeutic outcomes for patients. This review discusses traditional and emerging biomarkers of potential clinical utility for patients with metastatic colorectal cancer, current assays and methods used in clinical practice, technologies that have allowed the identification of new biomarkers and key considerations for oncologists and pathologists when determining appropriate biomarker evaluations to be undertaken for their patients.

show abstract

“…In patients with KRAS mutations, those with high levels of hepatocyte growth factor (HGF) or epiregulin (EREG) have shorter progression-free survival and overall survival compared with those with low levels of HGF or EREG (Takahashi et al 2014 ). One study has explored miRNAs as biomarkers of response to anti-EGFR MAbs and found that MiR-99a/Let-7c/miR-125b signature may improve the selection of patients with KRAS wild-type mCRC as good candidates for this therapy (Cappuzzo et al 2014 ).…”

Section: Chemogenomic Approach To Drug Resistancementioning

confidence: 97%